Lucy B. Palmer

TL;DR: These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia.

TL;DR: In critically ill patients with ventilator-associated tracheobronchitis, AA decrease VAP and other signs and symptoms of respiratory infection, facilitate weaning, and reduce bacterial resistance and use of systemic antibiotics.

TL;DR: Aerosol delivery in ventilated patients can be efficient and reproducible only if defined ventilator parameters are tightly controlled, and key parameters can be determined via in vitro bench testing defining delivery standards for clinical trials of drugs with narrow therapeutic/toxicity ratios.

TL;DR: In this clinical model, aerosolized antibiotics can make a significant impact on respiratory secretions and their efficacy in treatment of critically ill patients remains to be determined.

TL;DR: Assessment of nebulizer type, ventilator settings, volume fill, and humidification as well as technical factors affecting measurement of deposition in patients supported by mechanical ventilation to assess nebulized aerosol delivery to ventilated patients under optimal conditions.